Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s11934-016-0592-4.pdf
Reference64 articles.
1. Bach C et al. The status of surgery in the management of high-risk prostate cancer. Nat Rev Urol. 2014;11(6):342–51.
2. Yossepowitch O et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53(5):950–9.
3. Chang AJ et al. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–23. This excellent review provides an overview of the current state of prostate cancer management with a focus on optimal design for future studies.
4. Mitchell JA et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173(4):1126–31.
5. Cha EK, Eastham JA. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. Urol Oncol. 2015;33(5):217–25.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10
2. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer;Nature Reviews Urology;2024-08-07
3. The Molecular Biology of Prostate Cancer Stem Cells: From the Past to the Future;International Journal of Molecular Sciences;2023-04-19
4. Neoadjuvant Therapy for Locally Advanced or Oligometastatic Prostate Cancer: a Retrospective Comparative Single-Center Study;Indian Journal of Surgery;2022-04-11
5. Role of prostate cancer stem-like cells in the development of antiandrogen resistance;Cancer Drug Resistance;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3